BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHYMODIACTIN (chymopapain) is an injectable proteolytic enzyme approved in 1982 for intradiscal injection to treat intervertebral disc herniation. It works by enzymatically degrading the nucleus pulposus of herniated discs to relieve nerve compression and associated pain. This was a pioneering minimally invasive alternative to open discectomy surgery.
LOE Approaching
Late-stage product with moderate competitive pressure (30/100) indicating limited growth opportunity and a contracting commercial team focused on maintenance and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's LOE status and minimal investment in workforce expansion. Roles available are typically maintenance-focused: managing existing customer relationships, defending market position, and optimizing profitability rather than driving growth or innovation.
Brand ManagerRegional Sales Manager
Worked on CHYMODIACTIN at Discure Technologies? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.